Merck discontinues osteoporosis drug development on increased risk of stroke
An independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke. The company said while odanacatib reduces the risk of osteoporotic fractures, the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.